Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer-Reference-Cited by-同舟云学术

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

Published:2021-11 Issue:2 Volume:163 Page:274-280
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

O'Malley David M.,Oaknin Ana,Monk Bradley J.,Selle Frédéric,Rojas Carlos,Gladieff Laurence,Berton Dominique,Leary Alexandra,Moore Kathleen N.,Estevez-Diz Maria D.P.,Hardy-Bessard Anne-Claire,Alexandre Jérôme,Opperman Christina P.,de Azevedo Carla Rameri A.S.,Randall Leslie M.,Feliu Waldo Ortuzar,Ancukiewicz Marek,Ray-Coquard Isabelle

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference28 articles.

1. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis;Arbyn;Lancet Glob. Health,2020

2. Cancer Stat Facts: Cervical Cancer;NCI Surveillance E, and End Results Program,2020

3. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: where do we stand? A literature review;Boussios;Crit. Rev. Oncol. Hematol.,2016

4. Targeted therapies in gynaecological cancers;Crusz;Histopathology.,2020

5. PD-1/PD-L1 inhibitors in cervical Cancer;Liu;Front. Pharmacol.,2019

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study;Advances in Therapy;2024-09-14

2. Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I);Taiwanese Journal of Obstetrics and Gynecology;2024-09

3. Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy;Frontiers in Oncology;2024-08-05

4. Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer;Journal for ImmunoTherapy of Cancer;2024-08

5. Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open‐label, multicenter, phase Ib trial;Cancer Communications;2024-07-23